Zobrazeno 1 - 7
of 7
pro vyhledávání: '"Ludmila Zubarovskaya"'
Autor:
Annalisa Ruggeri, Nicole Santoro, Jacques-Emmanuel Galimard, Krzysztof Kalwak, Mattia Algeri, Ludmila Zubarovskaya, Krzysztof Czyzewski, Elena Skorobogatova, Petr Sedlacek, Caroline Besley, Adriana Balduzzi, Yves Bertrand, Julia Peristeri, Franca Fagioli, Mariane Ifversen, Jolanta Gozdzik, Christina Peters, Birgitta Versluijs, Alessandra Biffi, Arcangelo Prete, Maura Faraci, Ibrahim Ghemlas, Ivana Bodova, Olga Aleinikova, Arnaud Dalissier, Vanderson Rocha, Selim Corbacioglu
Publikováno v:
Haematologica, Vol 999, Iss 1 (2024)
In children with acute myeloid leukemia (AML) who lack an HLA identical sibling, the donor can be replaced with an HLA matched unrelated donor (MUD) or a haploidentical donor (haplo). We compared outcomes of patients
Externí odkaz:
https://doaj.org/article/0cbd8179ddf14c39a5bebdf419f8d1ed
Autor:
Elena Morozova, Olesya Paina, Elena Semenova, Tatyana Gindina, Ludmila Zubarovskaya, Alexander Kulagin, Anna Osipova, Tatiana Bykova
Publikováno v:
EJC Paediatric Oncology, Vol 2, Iss , Pp 100073- (2023)
Externí odkaz:
https://doaj.org/article/8ae32f41eb714622b1ae607c4a472fa2
Autor:
Bhagirathbhai Dholaria, Myriam Labopin, Jaime Sanz, Annalisa Ruggeri, Jan Cornelissen, Hélène Labussière-Wallet, Didier Blaise, Edouard Forcade, Patrice Chevallier, Anna Grassi, Ludmila Zubarovskaya, Jürgen Kuball, Patrice Ceballos, Fabio Ciceri, Frederic Baron, Bipin N. Savani, Arnon Nagler, Mohamad Mohty
Publikováno v:
Journal of Hematology & Oncology, Vol 14, Iss 1, Pp 1-11 (2021)
Abstract Background Allogeneic hematopoietic cell transplantation (allo-HCT) using a mismatched unrelated donor (MMUD) and cord blood transplantation (CBT) are valid alternatives for patients without a fully human leukocyte antigen (HLA)-matched dono
Externí odkaz:
https://doaj.org/article/4b69962bfcce4270819a8ca50110c0d2
Autor:
Nikolai Tcvetkov, Artem Gusak, Elena Morozova, Ivan Moiseev, Vadim Baykov, Maria Barabanshikova, Kirill Lepik, Evgenyi Bakin, Julia Vlasova, Anna Osipova, Ludmila Zubarovskaya, Boris Afanasyev
Publikováno v:
Leukemia Research Reports, Vol 14, Iss , Pp 100215- (2020)
Aims: In our single-center retrospective study we evaluated whether level of different checkpoint molecules in bone marrow biopsies at diagnosis affect the clinical course of patients with myelodysplastic syndrome (MDS). Methods and results: A consec
Externí odkaz:
https://doaj.org/article/704462297bae4eef881234107ba1f547
Autor:
Andrey Kozlov, Maria Estrina, Olesia Paina, Tatiana Bykova, Anna Osipova, Polina Kozhokar, Zhemal Rakhmanova, Irina Solodova, Elena Morozova, Alexander Alyansky, Irina Kulagina, Asmik Gevorgian, Anna Dotsenko, Ivan Moiseev, Alexey Chukhlovin, Alexander Kulagin, Sergey Bondarenko, Elena Semenova, Ludmila Zubarovskaya
Publikováno v:
Pharmaceuticals, Vol 14, Iss 8, p 808 (2021)
Chronic graft versus host disease (cGVHD) remains a major complication of allogeneic hematopoietic stem cell transplantation (allo-HSCT). It significantly decreases survival and quality of life. The present study demonstrates retrospective data on ex
Externí odkaz:
https://doaj.org/article/6d8d38968b5c4e9da8071775e75a7146
Autor:
Paul A. Carpenter, Hyoung Jin Kang, Keon Hee Yoo, Marco Zecca, Bin Cho, Giovanna Lucchini, Eneida R. Nemecek, Kirk R. Schultz, Polina Stepensky, Sonali Chaudhury, Benjamin Oshrine, Seong Lin Khaw, Andrew C. Harris, Marta Verna, Ludmila Zubarovskaya, Yihua Lee, Justin Wahlstrom, Lori Styles, Peter J. Shaw, Jean-Hugues Dalle
Publikováno v:
Transplantation and Cellular Therapy. 28:S103-S104
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::72fd81de6ef80b06a523f8696d8e39a9
https://doi.org/10.1016/s2666-6367(22)00287-1
https://doi.org/10.1016/s2666-6367(22)00287-1
Autor:
Asmik Gevorgian, Polina Tolkunova, Ilya Kazantsev, Tatiana Iukhta, Andrew Kozlov, Darya Zvyagintseva, Elena Morozova, Ludmila Zubarovskaya, Boris Afanasiev, Olga Zheludkova, Yury Punanov
Publikováno v:
Neuro-Oncology
AIM Medulloblastoma is a highly lethal disease when it recurs. Very few patients survive with second line conventional treatment after relapse. This study evaluated the use of high-dose thiotepa, carboplatin and etoposide with autologous hematopoieti
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::4a3056e805219b7b23317b5867871c8c
http://europepmc.org/articles/PMC7715147
http://europepmc.org/articles/PMC7715147